 |
|
Uterine Sarcoma Trial Results
Surgery Alone May Be Best for Early Endometrial Cancer
(Posted: 01/14/2009) - Results from a large international clinical trial show no evidence of benefit in terms of overall or recurrence-free survival for pelvic lymphadenectomy in women with early endometrial cancer, according to the Jan. 10, 2009, issue of the Lancet.
Ifosfamide Plus Paclitaxel Extends Life for Patients With Uterine Carcinosarcoma
(Posted: 03/05/2007) - Women with a rare, aggressive form of uterine cancer who were treated with the drugs ifosfamide and paclitaxel lived a median of five months longer than women who were treated with ifosfamide alone, according to the Feb. 10, 2007, Journal of Clinical Oncology.
Chemotherapy Superior to Whole-Abdominal Radiation Therapy for Uterine Sarcoma
(Posted: 06/27/2006) - Chemotherapy with cisplatin and ifosfamide was more effective than whole-abdominal radiation therapy at extending survival in patients with uterine sarcoma, according to findings presented at the 2006 meeting of the American Society of Clinical Oncology.
Tamoxifen Poses Slightly Greater Risk of Uterine Sarcoma
(Posted: 05/20/2002, Reviewed: 10/31/2005) - It's been known that tamoxifen - a commonly prescribed treatment and prevention drug for breast cancer - increases the risk of endometrial cancer (cancer of the lining of the uterus). Now researchers with a large breast cancer study project and representatives from the U.S. Food and Drug Administration (FDA) report that tamoxifen also slightly raises the risk of uterine sarcoma, a rare cancer of the muscles or other supporting tissue of the uterus.
|
|
|
